Stefaan:
I assume you mean Caliper's (not Zymark's) management?
To me, Caliper's purchase of Zymark and of its CEO makes sense. By itself, Zymark looks like a pretty solid operation based on its web site (www.zymark.com). It's Berwind Group parent (www.berwind.com) is pretty diverse, but does have (in addition to Zymark) a Pharmaceutical Services division.
And after browsing through Berwind's Pharmaceutical division (which did not include Zymark), I am guessing that Zymark fits better into Caliper than into Berwind. But of course I am sure there are "stories" behind the merger, at both the Caliper and Berwind ends, and I'd sure like to know what they are. But not knowing that, all I can do is look at whatever evidence I can find.
Zymark's CEO (Hrusovsky) apparently has a successful management background, and many links to the Pharmaceutical industry, and based on his Zymark (and previous) experience he might be just what Caliper needs as a CEO. Moving Knapp to chief technology officer may put him where is comparative advantage lies.
I find Caliper's technology quite impressive, and using Zymark as a source of new management and as a source of continuing funds for research may work.
I don't own Caliper, but I'm thinking about it very seriously.
If you have some counter arguments, I'd sure like to know what they are, because I didn't start following CALP until today.
Roger Folsom |
